Presenting data at the Bascom Palmer Eye Institute’s Angiogenesis, Exudation and Degeneration 2012 meeting in Miami, Florida, Dr. Pravin Dugel announced the results of a Phase 3 24 month study (the CABERNET trial) evaluating epimacular brachytherapy for the treatment of wet AMD. The study did not achieve its primary endpoint of losing fewer than 15 letters of vision leaving future development of the therapy in uncertain territory. NeoVista Inc, the US based sponsor of the targeted strontium-90 beta radiation treatment, have not yet released detailed analysis and have not provided any comment on the company website at time of writing.
CABERNET study fails to meet primary endpoint at 24 months
- by swdadmin